Back to search
FDAFDA · Food and drugs·Recall number D-168-2013

EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltration Only. Not for any other route of administration. Manufactured by Paelra Pharmaceuticals. Inc., San Diego, California, USA

Published March 6, 2013 · Recall initiated: December 17, 2012

Summary

FDA records drug Class II recall D-168-2013, published March 6, 2013 and initiated December 17, 2012. Recalling firm: Pacira Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 324 vials; Lot: Lot #11-2005 Control #23542 Manufacture Date: 05Dec11 2011-L-009. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent; bupivacaine

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pacira Pharmaceuticals, Inc.
Distributor
Nationwide distribution: AZ, DC, FL, GA, MA, NJ, NY, OH, and TX.
Lot
Lot #11-2005 Control #23542 Manufacture Date: 05Dec11 2011-L-009
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltration Only. Not for any other route of administration. Manufactured by Paelra Pharmaceuticals. Inc., San Diego, California, USA recalled?

Yes. FDA published recall D-168-2013 on March 6, 2013. Reported hazard: Subpotent; bupivacaine

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit